May 10, 2017
The combination of SPECT/CT and fluorescence imaging could help surgeons differentiate tumor tissue from normal tissue in patients with colorectal cancer, according to a paper published in the May issue of the Journal of Nuclear Medicine.
Researchers from the Netherlands used a mouse model to show that pulmonary micrometastases of colorectal cancer can be identified with labetuzumab labeled with both a near-infrared fluorescent dye (IRDye800CW) and indium-111 (JNM, May 2017, Vol. 58:5, pp. 706-710). Labetuzumab is an antibody developed by Immunomedics that targets carcinoembryonic antigen (CEA), which is overexpressed in approximately 95% of colorectal cancer cases.